Rheumatology Medical News

Become a Member Today!
Register

Most Viewed Abstracts

1. Report Shows Shift in Starting Salaries for Physicians

2. Rapid correction of low vitamin D status in nursing home residents

3. 2008 Exclusive Survey—Earnings: Good news for primary care income

4. Medicare pay-for-reporting effort draws fire from frustrated doctors

5. Allopurinol-induced recurrent dress syndrome: Pathophysiology and treatment

Your Article Summary

See Latest Articles

(Click the title below to leave the MDLinx Network and go to the Journal's Website)

Cost-effectiveness of two therapeutic regimens of infliximab in ankylosing spondylitis: economic evaluation within a randomized controlled trial
Annals of Rheumatic Diseases, 09/23/09

Fautrel B et al. – The administration of infliximab every 6 weeks is cost-effective as compared with a DEM regimen; however, the ICER is close to the acceptability threshold of 50,000 for one QALY gained.

Methods

230 patients with active AS
2 infliximab infusion modalities – every 6 weeks (Q6) and on demand (DEM) included in an economic evaluation within the trial
Data collected by phone every 3 months for 1 year
Direct and indirect costs calculated from a payer perspective
Health-related quality of life assessed with a general health rating scale
ICERs were calculated for one 20% improvement (ASAS20), for one partial remission and for one quality-adjusted life year (QALY) gained

Results

Q6 regimen significantly more efficacious than the DEM regimen but also more costly (22,388 vs 17,596)
Required significantly more infliximab infusions per patient
ICERs of the Q6 to DEM regimen were 15,841 for one ASAS20 response, 23,296 for one partial remission and 50,760 for one QALY gained

<< Previous
Effects of denosumab on bone mineral density and bone turnover in...

Next >>
Differences in the radiological characteristics between...